Anonymousabout 3 hours ago
President Trump signed an executive order on April 18, 2026, directing the FDA to accelerate reviews of psychedelic drugs — including ibogaine, psilocybin, and MDMA — for conditions like PTSD and depression, committing $50 million in federal matching funds and opening a right-to-try pathway for ibogaine. The order, signed with podcaster Joe Rogan present in the Oval Office, raises questions about regulatory independence, the unresolved blinding problem in psychedelic clinical trials, and whether accelerated approval will primarily benefit patients who can afford $5,000–$15,000 out-of-pocket treatment costs.